Adeno-associated virus vector
The novel AAV vector particles with modified capsid proteins and self-complementary structures address the inefficiencies of conventional AAV vectors by enhancing gene expression efficiency and infection rates, enabling more effective gene delivery in both dividing and non-dividing cells.
Patent Information
- Application Number
- PCT/JP2024/018340
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-17
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-21
AI Technical Summary
Current AAV vectors face challenges in achieving high expression efficiency due to the inefficiency of converting single-stranded DNA to double-stranded DNA, which limits the size of genes that can be transported and requires large amounts of vector and time for gene expression.
Development of novel AAV vector particles with modified capsid proteins VP1, VP2, and VP3, specifically with altered amino acid sequences and ratios, to enhance infection efficiency and gene expression, including self-complementary AAV vectors that quickly form double-stranded DNA in target cells.
The modified AAV vectors demonstrate improved gene transfer efficiency and prolonged gene expression in both dividing and non-dividing cells, overcoming the limitations of conventional AAV vectors by increasing the ratio of VP1 and VP2 to VP3 in the capsid, resulting in higher infection efficiency and more effective gene delivery.
Smart Images

Figure JPOXMLDOC01-APPB-T000001 
Figure JPOXMLDOC01-APPB-T000002 
Figure JPOXMLDOC01-APPB-T000003
Abstract
Description
Adeno-associated virus vector
[0001] The present disclosure relates to the field of gene therapy. More specifically, the present disclosure provides novel AAV vector particles. The present disclosure also provides kits for preparing AAV vectors.
[0002] There are two types of gene therapy: in vivo gene therapy, in which genes are introduced into cells in the body, and ex vivo gene therapy, in which genes are introduced into cells removed from the body and then returned to the body. Viral vectors, which have high transduction efficiency, are generally used to introduce genes into cells. Examples of viruses that can be used as viral vectors include retroviruses, lentiviruses, adenoviruses, and adeno-associated viruses (AAVs). Viral vectors are selected depending on the purpose of treatment and the target cells.
[0003] AAV has been isolated from human upper respiratory tract mucosa, but its pathogenicity is unknown. AAV is a molecular complex composed of a protein capsid and encapsulated genomic DNA. There are 11 serotypes (types 1 to 11) of AAV that can infect human cells. AAV genomic DNA is a single-stranded DNA molecule of approximately 4.7 kb. It contains two major regions encoding nonstructural Rep (replication) proteins and structural Cap (capsid) proteins. The major regions contain two inverted terminal repeat (ITR) sequences, each approximately 145 nucleotides long. The ITR sequences function as primers for the initiation of genomic DNA replication. The ITR sequences may also be involved in the integration of genomic DNA into viral particles and its rescue from the host genome.
[0004] An AAV capsid generally contains three types of capsid proteins, termed VP1, VP2, and VP3, in a stoichiometric ratio of approximately 1:1:10, with a total of 60 copies of these proteins per capsid. AAV2 VP3 includes a 533-amino acid-long VP3 and a 525-amino acid-long VP3 variant (also referred to as "clipped VP3" or "VP3 clip") (Non-Patent Document 1).
[0005] AAV-derived viral vectors (hereinafter also referred to as "AAV vectors") are capable of gene transfer not only into dividing cells but also into non-dividing cells. AAV vectors can efficiently transfer genes into non-dividing cells, and gene expression in non-dividing cells persists for a long period of time. AAV is non-pathogenic and safe, making it advantageous as a viral vector. Due to these properties, AAV vectors are expected to be used as vectors for gene therapy. Since tissue characteristics differ depending on the AAV serotype, AAV vectors of different serotypes are used depending on the type of target cell.
[0006] Since the AAV genome is single-stranded DNA, it must become double-stranded for gene expression to occur. Because the process of becoming double-stranded is not highly efficient, a large amount of vector and time are required to achieve a certain level of expression. Self-complementary AAV (scAAV) vectors have been developed that streamline the process of becoming double-stranded. In scAAV vectors, the plus and minus strands of the genome are ligated to form a double-stranded structure. Compared to conventional single-stranded AAV vectors (ssAAV vectors), scAAV vectors quickly become double-stranded in target cells, allowing for efficient and rapid gene expression. Since the genome size of the plus or minus strand carried by the scAAV vector is half, the genes that can be transported are limited to those of small size.
[0007] Recombinant AAV has been developed using a baculovirus expression vector system (Non-Patent Document 2). Non-Patent Document 2 suggests that the balance of the stoichiometric ratio of viral proteins (VP) 1 to 3 in rAAV affects infection efficiency. An assembly model of AAV is known in which AAV capsids are constructed by random drawing 60 times from a mixed pool of VP1, VP2, and VP3, and the constituent ratios of VP1, VP2, and VP3 that constitute the capsid depend on the relative expression levels of VPs in the pool (Non-Patent Document 3). Non-Patent Document 3 indicates that the produced AAV particle population is a mixture of various AAV particles with different constituent ratios of VP1 to VP3.
[0008] Human Gene Therapy 2021 (32) 21-22:1403-1416 Gene Therapy (2018) 25:415-424 Nature Communications (2021) 12:1642, pp. 1-9
[0009] There is a need in the field of gene therapy for methods to increase the expression efficiency of AAV vectors.
[0010] An object of the present disclosure is to provide a novel AAV vector. Specifically, an object of the present disclosure is to provide a novel AAV vector that has improved cell infection efficiency and thereby improved efficiency of gene transfer carried by the AAV vector. More specifically, the present disclosure provides the following inventions. [Item 1] An adeno-associated virus (AAV) vector particle comprising a capsid, wherein the capsid comprises capsid proteins VP1, VP2, and VP3, and the VP3 is (A) a polypeptide consisting of the amino acid sequence set forth in any one of SEQ ID NOS: 1 to 6 and 25 to 29; or (B) a polypeptide capable of forming the capsid, which comprises an amino acid sequence that contains a deletion, substitution, or addition, or a combination thereof, in the amino acid sequence of the polypeptide of (A), and which has at least 80% sequence identity with the amino acid sequence corresponding to amino acids 18 to 533 of the amino acid sequence set forth in SEQ ID NO: 1, and wherein the ratio of the number of VP1 and VP2 to the number of VP3 in the capsid ([VP1 + VP2] / [VP3]) is 0.3 or greater. [Item 2] An adeno-associated virus (AAV) vector particle comprising a capsid, wherein the capsid comprises capsid protein VP3, and the VP3 is (A) a polypeptide consisting of the amino acid sequence set forth in any one of SEQ ID NOs: 7 to 18; or (B) an amino acid sequence that contains a deletion, substitution, or addition, or a combination thereof, in the amino acid sequence of the polypeptide of (A), and that has at least 80% sequence identity with the amino acid sequence corresponding to amino acids 18 to 533 of the amino acid sequence set forth in SEQ ID NO: 1, and is capable of forming the capsid.
[0011] [Item 3] The AAV vector particle according to Item 1, wherein when the polypeptide of (B) has an amino acid (referred to as "1st AA" or "9th AA") at a position corresponding to position 1 or 9 of the amino acid sequence set forth in SEQ ID NO: 1, the 1st AA or 9th AA is an amino acid selected from the group consisting of methionine, glycine, isoleucine, proline, and serine, and when an amino acid sequence corresponding to positions 2 to 8 of the amino acid sequence set forth in SEQ ID NO: 1 (referred to as "2nd-8th AA") is present, the amino acid sequence corresponding to the 2nd-8th AA is and / or, when an amino acid sequence corresponding to the amino acid sequence from positions 10 to 17 of the amino acid sequence set forth in SEQ ID NO: 1 (referred to as "10th-17thAA") is present, the amino acid sequence corresponding to the 10th-17thAA comprises an amino acid sequence comprising a deletion, substitution, or addition, or a combination thereof, in the 10th-17thAA and having at least 70% sequence identity with the 10th-17thAA.[Item 4] The AAV vector particle according to Item 2, wherein, in the polypeptide of (B), when the 1st AA or 9th AA of the amino acid sequence set forth in SEQ ID NO: 1 is present, the 1st AA or 9th AA is an amino acid selected from the group consisting of valine, glycine, isoleucine, proline, and serine, and when an amino acid sequence corresponding to the 2nd-8th AA of the amino acid sequence set forth in SEQ ID NO: 1 is present, the amino acid sequence corresponding to the 2nd-8th AA is a deletion, substitution, addition, or and / or, when an amino acid sequence corresponding to a 10th-17th AA of the amino acid sequence set forth in SEQ ID NO: 1 is present, the amino acid sequence corresponding to the 10th-17th AA comprises a deletion, substitution, or addition, or a combination thereof, in the 10th-17th AA and consists of an amino acid sequence having at least 70% sequence identity with the 10th-17th AA.
[0012] [Item 5] The AAV vector particle according to Item 2, wherein the ratio of the sum of the number of VP1 and the number of VP2 to the number of VP3 in the capsid ([VP1 + VP2] / [VP3]) is 0.3 or more. [Item 6] The AAV vector particle according to any one of Items 1 to 5, wherein the AAV vector particle comprises a nucleic acid molecule comprising a predetermined nucleotide sequence. [Item 7] A nucleic acid molecule comprising a polynucleotide sequence encoding VP1, VP2, and VP3, wherein VP3 is (A) a polypeptide consisting of the amino acid sequence set forth in any of SEQ ID NOs: 7 to 18; or (B) a polypeptide which comprises an amino acid sequence of the polypeptide of (A) that contains a deletion, substitution, or addition, or a combination thereof, and has at least 80% sequence identity with the amino acid sequence corresponding to amino acids 18 to 533 of the amino acid sequence set forth in SEQ ID NO: 1, and is capable of forming the capsid. [Item 8] A kit for preparing an AAV vector particle, comprising a first nucleic acid molecule and a second nucleic acid molecule, wherein the first nucleic acid molecule comprises a capsid protein coding region and a Rep region, and the second nucleic acid molecule comprises a first adeno-associated virus (AAV) inverted terminal repeat (ITR) sequence; a predetermined nucleotide sequence; and a second AAV-ITR sequence, in this order, the capsid protein coding region comprises a polynucleotide sequence encoding VP1, VP2, and VP3, wherein VP3 is (A) a polypeptide consisting of the amino acid sequence set forth in any of SEQ ID NOs: 7 to 18; or (B) a polypeptide which comprises a deletion, substitution, or addition, or a combination thereof, in the amino acid sequence of the polypeptide of (A), and which consists of an amino acid sequence having at least 80% sequence identity with the amino acid sequence corresponding to amino acids 18 to 533 of the amino acid sequence set forth in SEQ ID NO: 1, and which is capable of forming the capsid. [Item 9] An AAV vector particle composition, comprising the AAV vector particles according to any one of Items 1 to 6 in a proportion of 50% or more relative to the total number of moles of the capsids. [Item 9-1] An AAV vector particle composition, comprising the AAV vector particles according to any one of Items 1 to 5 in a proportion of 50% or more relative to the total number of moles of the capsids.[Item 9-2] An AAV vector particle composition, comprising the AAV vector particles according to Item 6 in a proportion of 50% or more relative to the total number of moles of the capsid.
[0013] [Item 10] A pharmaceutical composition comprising the AAV vector particle of any one of Items 1 to 6, or the AAV vector particle composition of any one of Items 9 to 9-2. [Item 10-1] A pharmaceutical composition comprising the AAV vector particle of any one of Items 1 to 5. [Item 10-2] A pharmaceutical composition comprising the AAV vector particle of Items 6. [Item 10-3] A pharmaceutical composition comprising the AAV vector particle composition of any one of Items 9 to 9-2. [Item 11] An in vitro method for inducing transcription and / or expression of a predetermined nucleotide sequence in a mammalian cell, the method comprising contacting the AAV vector particle of any one of Items 1 to 6 with a mammalian cell, and placing the cell under conditions that allow transcription and / or expression of the predetermined nucleotide sequence. [Item 11-1] An in vitro method for inducing the transcription and / or expression of a predetermined nucleotide sequence in a mammalian cell, the method comprising contacting a mammalian cell with the AAV vector particle of Item 6 and placing the cell under conditions that allow the transcription and / or expression of the predetermined nucleotide sequence. [Item 12] An in vitro method for inducing the transcription and / or expression of a predetermined nucleotide sequence in a mammalian cell, the method comprising contacting a mammalian cell with the AAV vector particle composition of any one of Item 9 to 9-2 and placing the cell under conditions that allow the transcription and / or expression of the predetermined nucleotide sequence.
[0014] Figure 1A is a photograph of crudely purified rAAV2 particles after ultracentrifugation. Figure 1B is a photograph of rAAV2 particles corresponding to the F1 band after ultracentrifugation. Figure 1C is a photograph of rAAV2 particles corresponding to the F2 band after ultracentrifugation. Figure 2A is a graph showing the absorbance results obtained by capillary gel electrophoresis of rAAV2 particles corresponding to the Bulk band observed in Figure 1A. Figure 2B is a graph showing the absorbance results obtained by capillary gel electrophoresis of rAAV2 particles corresponding to the F1.1 band observed in Figure 1B. Figure 2C is a graph showing the absorbance results obtained by capillary gel electrophoresis of rAAV2 particles corresponding to the F2.2 band observed in Figure 1C. Figure 3A is a graph showing the sedimentation coefficient of rAAV2 particles corresponding to the F1.1 band observed in Figure 1B. Figure 3B is a graph showing the sedimentation coefficient of rAAV2 particles corresponding to the F2.2 band observed in Figure 1C. Figure 4 is a bar graph showing the constituent ratios of capsid proteins constituting rAAV2 capsids. Figure 5 is a graph showing the EGFP gene transfer efficiency of rAAV2 particles. Figure 6 is a bar graph showing the titers of rAAV2 variants. Figure 7A is a graph showing the absorbance results obtained by subjecting wild-type (WT)-rAAV2 particles to capillary gel electrophoresis. Figure 7B is a graph showing the absorbance results obtained by subjecting the M203V-rAAV2 variant to capillary gel electrophoresis. Figure 7C is a graph showing the absorbance results obtained by subjecting the M211V-rAAV2 variant to capillary gel electrophoresis. Figure 7D is a graph showing the results of mass analysis of a single particle of WT-rAAV2 particles by charge detection mass spectrometry (CD-MS). Figure 7E is a graph showing the results of mass analysis of a single particle of the M203V-rAAV2 variant by CD-MS. Figure 7F is a graph showing the results of mass analysis of a single particle of the M211V-rAAV2 variant by CD-MS. Figure 8A is a graph showing the absorbance of purified wild-type (WT) AAV2 capsid protein. Figure 8B is a graph showing the absorbance of purified M203V-AAV2 variant capsid protein. Figure 8C is a graph showing the absorbance of purified M211V-AAV2 variant capsid protein.Figure 8D is a graph showing the results of mass spectrometry analysis of VP3 and VP3 clip of WT-rAAV2 particles. Figure 8E is a graph showing the results of mass spectrometry analysis of VP3 and VP3 clip of M203V-rAAV2 variant particles. Figure 8F is a graph showing the results of mass spectrometry analysis of VP3 and VP3 clip of M211V-rAAV2 variant particles. Figure 9 is a bar graph showing the composition ratio of capsid proteins constituting the capsid of AAV2 variants. Figure 10(a) is a graph showing the gene transfer efficiency into HeLa RC32 cells. Figure 10(b) is a graph showing the gene transfer efficiency into HEK293T cells. Figure 10(c) is a graph showing the gene transfer efficiency into HeLa RC32 cells using rAAV2 particles prepared separately from the rAAV2 particles used in Figure 10(a). Figure 11A is a bar graph showing the constituent ratio of capsid proteins for each rAAV2. Figure 11B is a bar graph showing the infection efficiency for each rAAV2. Figure 12 is a scatter plot showing the relationship between the constituent ratio of capsid proteins for each rAAV2 and infection efficiency.
[0015] Adeno-Associated Virus Vector Particles A first aspect of the present disclosure relates to adeno-associated virus (AAV) vector particles that include a capsid.
[0016] In one embodiment of the first aspect, the AAV vector particle comprises a capsid, the capsid comprising capsid proteins VP1, VP2, and VP3, and the VP3 is (A) a polypeptide consisting of an amino acid sequence set forth in any one of SEQ ID NOs: 1 to 6 and 25 to 29; or (B) a polypeptide comprising a deletion, substitution, or addition, or a combination thereof, in the amino acid sequence of the polypeptide of (A), and corresponding to amino acids 18 to 533 of the amino acid sequence set forth in SEQ ID NO: 1. the capsid is a polypeptide that can form the capsid and that consists of an amino acid sequence that has at least 80% (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more) sequence identity with the VP1 or VP2 sequence of the AAV vector particle, and the ratio of the sum of the number of VP1 and the number of VP2 to the number of VP3 in the capsid ([VP1+VP2] / [VP3]) is 0.3 or more (0.32 or more, 0.34 or more, or 0.35 or more). In this embodiment, the AAV vector particle comprises a nucleic acid molecule that includes a predetermined nucleotide sequence.
[0017] In one embodiment according to the first aspect, the AAV vector particle comprises a capsid, and the capsid comprises capsid proteins VP1, VP2, and VP3. VP3 is (A) a polypeptide consisting of the amino acid sequence set forth in any of SEQ ID NOs: 7 to 18; or (B) a polypeptide that contains a deletion, substitution, or addition, or a combination thereof, in the amino acid sequence of the polypeptide of (A), and that consists of an amino acid sequence that has at least 80% (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more) sequence identity with the amino acid sequence corresponding to amino acids 18 to 533 of the amino acid sequence set forth in SEQ ID NO: 1, and is capable of forming the capsid. In this embodiment, the ratio of the sum of the number of VP1 and the number of VP2 to the number of VP3 in the capsid ([VP1+VP2] / [VP3]) is 0.3 or more (0.32 or more, 0.34 or more, or 0.35 or more). In this embodiment, the AAV vector particle comprises a nucleic acid molecule comprising a predetermined nucleotide sequence.
[0018] The term "adeno-associated virus (AAV)" refers to a molecular complex composed of capsid proteins and genomic DNA, classified in the Parvoviridae family, Parvovirinae subfamily, Dependovirus genus.
[0019] The term "AAV vector particle" refers to a particle derived from AAV that has the ability to infect cells. AAV vector particles can be prepared according to known methods or the methods disclosed herein. The AAV vector particles can be used, for example, in gene therapy. The AAV vector particles can be used, for example, to deliver normal genetic material to mammalian cells containing a defective gene to treat a disease caused by the defective gene. The AAV vector particles can be administered to a mammal suffering from the disease (a subject in need thereof) by, for example, intraarterial injection, intravenous injection, or intraperitoneal injection. The AAV vector particles can be administered, for example, intraocularly, intramuscularly, intracardially, intraneurally, intrahepatically, intrarenally, or subcutaneously to a mammal suffering from the disease (a subject in need thereof).
[0020] The term "capsid" refers to an outer shell composed of multiple capsid proteins. The capsid has, for example, an internal space defined by the multiple capsid proteins. A capsid that does not contain a nucleic acid molecule is also referred to as a hollow particle or hollow capsid. A capsid that contains a nucleic acid molecule is also referred to as a complete particle, intermediate particle, or nucleocapsid. The complete particle, for example, contains a nucleic acid molecule having the entire length of a target sequence in the internal space. The intermediate particle, for example, contains a nucleic acid molecule having a portion of a target sequence in the internal space. The nucleocapsid, for example, contains a nucleic acid molecule in the internal space.
[0021] The AAV vector particle according to the first aspect may be, for example, an empty capsid, or a complete particle, an intermediate particle, or a nucleocapsid. In one embodiment, the AAV vector particle is an empty capsid. In another embodiment, the AAV vector particle is a complete particle, an intermediate particle, or a nucleocapsid.
[0022] The AAV capsid is composed of, for example, 60 capsid proteins. The "capsid protein" of AAV is viral protein 1 (VP1), VP2, or VP3. The multiple capsid proteins constituting the capsid include, for example, VP1, VP2, and VP3, with a total of 60 per capsid. VP1, VP2, and VP3 may each be encoded by a different gene (non-overlapping polypeptide regions). VP1, VP2, and VP3 are, for example, encoded by a single gene in the AAV Cap region. VP1 contains the amino acid sequence of VP2 in its C-terminal region. VP2 contains the amino acid sequence of VP3 in its C-terminal region. VP1, VP2, and VP3 may be encoded by a single gene, such as encoded by a single gene in the AAV Cap region. The amino acid sequences of VP1, VP2, and VP3 are available from, for example, public institutions (e.g., National Center for Biotechnology Information: NCBI). The capsid proteins may be post-translationally modified, for example, by phosphorylation, oxidation, glycosylation, or the like.
[0023] The amino acid sequences of VP1 and VP2 differ depending on, for example, the AAV serotype. VP1 and VP2 may be a combination of capsid proteins of the same AAV serotype (e.g., a combination of AAV2 VP1 and AAV2 VP2), or a combination of capsid proteins of different AAV serotypes (e.g., a combination of AAV10 VP1 and AAV2 VP2). VP1, VP2, and VP3 may all be a combination of capsid proteins of the same AAV serotype (e.g., a combination of AAV2 VP1 to VP3), or a combination of capsid proteins of different AAV serotypes (e.g., a combination of AAV2 VP1, AAV8 VP2, and AAV10 VP3). Serotypes may be mutants or chimeras. Serotypes include AAV-rh10, AAV-DJ, AAV-DJ / 8, AAV-PHP.eB, and AAV-PHP.S.
[0024] The amino acid sequences of VP1 and VP2 are, for example, polypeptides consisting of an amino acid sequence (A) derived from the same AAV serotype as VP3, or (B) polypeptides consisting of an amino acid sequence that contains deletions, substitutions, or additions, or a combination thereof, in the amino acid sequence of (A) and has at least 80% (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more) sequence identity with the amino acid sequence of (A), and that can form a capsid together with VP3. VP1, VP2, and VP3 are, for example, polypeptides consisting of the amino acid sequence (A) derived from the same AAV serotype, or (B) polypeptides consisting of an amino acid sequence that contains deletions, substitutions, or additions, or a combination thereof, in the amino acid sequence of (A) and has at least 80%, 85%, 90%, or 95% (e.g., 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more) sequence identity with the amino acid sequence of (A), and that can form a capsid together with VP3.
[0025] VP3 is, for example, a polypeptide consisting of any of the amino acid sequences (A) shown in the table below.
[0026]
[0027]
[0028]
[0029]
[0030]
[0031]
[0032]
[0033] The M203V-AAV2 VP3 variant (SEQ ID NO: 7) can be prepared from an amino acid sequence in which methionine at position 1 of WT-AAV2 VP3 (SEQ ID NO: 1) has been substituted with an amino acid other than methionine (e.g., valine), for example, a polynucleotide sequence encoding the amino acids set forth in SEQ ID NO: 19. The M203V-AAV1 VP3 variant (SEQ ID NO: 9) can similarly be prepared from an amino acid sequence in which methionine at position 1 of WT-AAV1 VP3 (SEQ ID NO: 2) has been substituted with an amino acid other than methionine (e.g., valine), for example, a polynucleotide sequence encoding the amino acids set forth in SEQ ID NO: 20. The M203V-AAV3 VP3 variant (SEQ ID NO: 11) can similarly be prepared from an amino acid sequence in which methionine at position 1 of WT-AAV3 VP3 (SEQ ID NO: 3) has been substituted with an amino acid other than methionine (e.g., valine), for example, a polynucleotide sequence encoding the amino acids set forth in SEQ ID NO: 21. The M203V-AAV1 VP10 variant (SEQ ID NO: 13) can also be prepared from an amino acid sequence in which the methionine at position 1 of WT-AAV10 VP3 (SEQ ID NO: 4) has been substituted with an amino acid other than methionine (e.g., valine), for example, a polynucleotide sequence encoding the amino acids set forth in SEQ ID NO: 22. The M203V-AAV1 VP6 variant (SEQ ID NO: 15) can also be prepared from an amino acid sequence in which the methionine at position 1 of WT-AAV6 VP3 (SEQ ID NO: 5) has been substituted with an amino acid other than methionine (e.g., valine), for example, a polynucleotide sequence encoding the amino acids set forth in SEQ ID NO: 23. The M203V-AAV1 VP8 variant (SEQ ID NO: 17) can also be prepared from an amino acid sequence in which the methionine at position 1 of WT-AAV8 VP3 (SEQ ID NO: 6) has been substituted with an amino acid other than methionine (e.g., valine), for example, a polynucleotide sequence encoding the amino acids set forth in SEQ ID NO: 24.
[0034] It is believed that the N-terminal amino acid sequence region of VP3 (the amino acid sequence region from positions 1 to 17 in the amino acid sequence set forth in SEQ ID NO: 1) exhibits a flexible structure that does not form a specific structure. This speculation is based on the fact that crystal structure analysis suggests that the N-terminal region does not form a specific structure, and on the results of the inventors' structural prediction (AlphaFold) that the N-terminal region does not form a specific structure. The amino acid sequence region that forms a specific structure, specifically the amino acid sequence region from positions 18 to 533 in the amino acid sequence set forth in SEQ ID NO: 1, is believed to be necessary for VP3 to maintain its ability to form capsids. In other words, it is inferred that the amino acid sequence of the Na-terminal region of VP3 (particularly the amino acid sequence from positions 1 to 17 in SEQ ID NO: 1) is not important for VP3's ability to form capsids.
[0035] In one embodiment, the capsid protein VP3 is (B) a polypeptide capable of forming the capsid, which comprises an amino acid sequence comprising a deletion, substitution, or addition, or a combination thereof, in the amino acid sequence set forth in any one of SEQ ID NOS: 1 to 6 and 25 to 29, and which has at least 80% (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more) sequence identity with the amino acid sequence corresponding to amino acids 18 to 533 of the amino acid sequence set forth in SEQ ID NO: 1, wherein the ratio of the sum of the number of VP1 and the number of VP2 to the number of VP3 in the AAV capsid ([VP1+VP2] / [VP3]) is 0.3 or more (0.32 or more, 0.34 or more, or 0.35 or more). When the AAV capsid contains 60 capsid proteins and the ratio is 0.3 or greater, [VP1 + VP2] is 13.85 or greater. Similarly, when the ratio is 0.32 or greater, 0.34 or greater, or 0.35 or greater, [VP1 + VP2] is 14.54 or greater, 15.22 or greater, or 15.55 or greater. In this embodiment, the VP3 is, for example, a polypeptide consisting of the amino acid sequence set forth in any one of SEQ ID NOs: 1 to 6, preferably a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 1 or 6. The VP3 is preferably a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 1 or 6.
[0036] In the embodiment, the polypeptide of (B) (i) has an amino acid (referred to as "1st AA" or "9th AA") at a position corresponding to 1 or 9 of the amino acid sequence set forth in SEQ ID NO: 1, wherein the 1st AA or 9th AA is an amino acid selected from the group consisting of methionine, glycine, isoleucine, proline, and serine.
[0037] The amino acid sequence near the N-terminus of AAV VP3 shows high sequence identity between specific serotypes. Specifically, when aligned with AAV2 VP3, AAV1, 3, and 6-10 VP3 show 71% sequence identity with the amino acid sequence corresponding to positions 204 to 210 of the VP1 amino acid sequence (corresponding to positions 2 to 8 of the amino acid sequence set forth in SEQ ID NO: 1 (AAV2 VP3)) (see the "Table" below). As described above, the amino acid sequence of the Na-terminal region of VP3 (particularly the amino acid sequence from positions 1 to 17 in SEQ ID NO: 1) is flexible and does not form a specific structure, and is therefore presumed not to be important for the capsid-forming properties of VP3. On the other hand, the amino acid sequence from positions 2 to 8 of VP3 of AAV1, 3, and 6-10 (the amino acid sequence from positions 204 to 210 in the VP1 amino acid sequence) shows high sequence identity (71%) with the amino acid sequence from positions 2 to 8 of AAV2 VP3. The effects demonstrated using AAV2 VP3 or VP3 variants in the examples of the present disclosure are believed to be achieved by VP3 variants that share high sequence identity (70% sequence identity) with the amino acid sequence of the Na-terminal region of AAV2 VP3.
[0038] In the above-mentioned embodiment, the polypeptide of (B) is such that (ii-a) when an amino acid sequence corresponding to the amino acid sequence from positions 2 to 8 of the amino acid sequence set forth in SEQ ID NO: 1 (referred to as "2nd-8th AA") is present, the corresponding amino acid sequence comprises a deletion, substitution, or addition, or a combination thereof, in the 2nd-8th AA, and consists of an amino acid sequence having at least 70% sequence identity with the 2nd-8th AA. In the above-mentioned embodiment, the polypeptide of (B) is such that (ii-b) when an amino acid sequence corresponding to the 2nd-8th AA of the amino acid sequence set forth in SEQ ID NO: 1 is present, the corresponding amino acid sequence comprises one or two deletions, substitutions, or additions, or a combination thereof, in the 2nd-8th AA.
[0039] In the above-mentioned embodiment, the polypeptide of (B) is such that (iii-a) when an amino acid sequence corresponding to the amino acid sequence from 10 to 17 (referred to as "10th-17thAA") of the amino acid sequence set forth in SEQ ID NO: 1 is present, the corresponding amino acid sequence comprises a deletion, substitution, or addition, or a combination thereof, in the 10th-17thAA, and has at least 70% sequence identity with the 10th-17thAA. In the above-mentioned embodiment, the polypeptide of (B) is such that (iii-b) when an amino acid sequence corresponding to the 10th-17thAA of the amino acid sequence set forth in SEQ ID NO: 1 is present, the corresponding amino acid sequence comprises one or two deletions, substitutions, or additions, or a combination thereof, in the 10th-17thAA.
[0040] In the above-mentioned embodiment, the polypeptide of (B) comprises the feature (i) and the feature (ii-a) or (ii-b). The polypeptide of (B) comprises the feature (i) and the feature (iii-a) or (iii-b). The polypeptide of (B) comprises the feature (ii-a) or (ii-b) and the feature (iii-a) or (iii-b). The polypeptide of (B) comprises the feature (i), the feature (ii-a) or (ii-b) and the feature (iii-a) or (iii-b).
[0041] Examples of the present disclosure demonstrated that the M203V-VP3 variant (SEQ ID NO: 7), in which methionine at position 9 in SEQ ID NO: 1 is N-terminal, enables the production of a homogeneous AAV vector particle population (FIG. 7B) and exhibits improved infection efficiency (see FIG. 11B, M203V). Examples of the present disclosure also demonstrated that the M211V-VP3 variant (SEQ ID NO: 8), in which methionine at position 9 in SEQ ID NO: 1 is substituted with valine, enables the production of a homogeneous AAV vector particle population (FIG. 7C) and exhibits improved infection efficiency (see FIG. 11B, M211V). There are 11 AAV serotypes (types 1 to 11). Among these, AAV1 VP3 (SEQ ID NO: 2), AAV3 VP3 (SEQ ID NO: 3), AAV10 VP3 (SEQ ID NO: 4), AAV6 VP3 (SEQ ID NO: 5), and AAV8 VP3 (SEQ ID NO: 6) have a methionine near the N-terminal (position 1), more specifically at position 9, similar to the VP3 of AAR2 used in the Examples of the present disclosure. The Examples of the present disclosure suggested that these AAVs may also produce rAAVs with relatively high and relatively low densities, similar to AAV2. It is believed that a uniform AAV vector particle population with improved infection efficiency can be obtained by introducing the same amino acid substitution (M203V or M211V) as in Example 2 of the present disclosure or a nonpolar neutral amino acid (glycine, isoleucine, proline, or serine) into the N-terminal methionine of VP3 of these AAVs or a methionine nearby. The methionine that serves as the translation initiation site may be lost during capsid formation.
[0042] In one embodiment, the capsid protein VP3 is (A) a polypeptide consisting of the amino acid sequence set forth in any one of SEQ ID NOs: 7 to 18 (VP3 (SEQ ID NOs: 1 to 6) of wild-type AAV types 2, 1, 3, 10, 6, and 8, respectively, having the amino acid substitution M203V or M211V). In this embodiment, the VP3 is, for example, a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 7, 8, 9, 10, 17, or 18. In this embodiment, the VP3 is preferably a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 7, 9, or 17. The VP3 is preferably a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 7, 8, 17, or 18. The VP3 is preferably a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 7 or 17.
[0043] In one embodiment, capsid protein VP3 is a polypeptide (B) consisting of an amino acid sequence which contains a deletion, substitution, or addition, or a combination thereof, in the amino acid sequence set forth in any one of SEQ ID NOs: 7 to 18, and which has at least 80% (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more) sequence identity with the amino acid sequence corresponding to positions 18 to 533 of the amino acid sequence set forth in SEQ ID NO: 1, and which is capable of forming the capsid. In this embodiment, the VP3 is, for example, a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 7, 8, 9, 10, 17, or 18. In this embodiment, the VP3 is preferably a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 7, 9, or 17. The VP3 is preferably a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 7, 8, 17, or 18. The VP3 is preferably a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 7 or 17.
[0044] In the embodiment, the polypeptide of (B) is such that (i) if the 1st AA or 9th AA of the amino acid sequence set forth in SEQ ID NO: 1 is present, the 1st AA or 9th AA is an amino acid selected from the group consisting of valine, glycine, isoleucine, proline, and serine.
[0045] In the above-mentioned embodiment, the polypeptide of (B) is such that (ii-a) when an amino acid sequence corresponding to the 2nd-8th AA of the amino acid sequence set forth in SEQ ID NO: 1 is present, the corresponding amino acid sequence comprises a deletion, substitution, or addition, or a combination thereof, in the 2nd-8th AA, and consists of an amino acid sequence having at least 70% sequence identity with the 2nd-8th AA. In the above-mentioned embodiment, the polypeptide of (B) is such that (ii-b) when an amino acid sequence corresponding to the 2nd-8th AA of the amino acid sequence set forth in SEQ ID NO: 1 is present, the corresponding amino acid sequence comprises one or two deletions, substitutions, or additions, or a combination thereof, in the 2nd-8th AA.
[0046] In the above-mentioned embodiment, the polypeptide of (B) is such that (iii-a) when an amino acid sequence corresponding to the 10th-17th AA of the amino acid sequence set forth in SEQ ID NO: 1 is present, the corresponding amino acid sequence comprises a deletion, substitution, or addition, or a combination thereof, in the 10th-17th AA, and has at least 70% sequence identity with the 10th-17th AA. In the above-mentioned embodiment, the polypeptide of (B) is such that (iii-b) when an amino acid sequence corresponding to the 10th-17th AA of the amino acid sequence set forth in SEQ ID NO: 1 is present, the corresponding amino acid sequence comprises one or two deletions, substitutions, or additions, or a combination thereof, in the 10th-17th AA.
[0047] In the above-mentioned embodiment, the polypeptide of (B) comprises the feature (i) and the feature (ii-a) or (ii-b). The polypeptide of (B) comprises the feature (i) and the feature (iii-a) or (iii-b). The polypeptide of (B) comprises the feature (ii-a) or (ii-b) and the feature (iii-a) or (iii-b). The polypeptide of (B) comprises the feature (i), the feature (ii-a) or (ii-b) and the feature (iii-a) or (iii-b).
[0048] The term "Kozak sequence" refers to a consensus sequence occurring in eukaryotic mRNA, which is involved in the initiation of translation of the polynucleotide sequence of the mRNA into its polypeptide sequence. -3 xxAUGX +4 "x" is any nucleoside. -3 " is the third nucleoside on the 5'-end side (upstream side) when the position of A in the initiation codon (AUG) is (+1). +4 " is the fourth nucleoside on the 3'-end (downstream) side, when the position of A in the initiation codon (AUG) is (+1). -3 is adenine or guanine (A / G), and X +4 When X is guanine (G), translation from the initiation codon is strongly induced, and this is called a "strong" Kozak sequence ((A / G)xxAUGG). -3 is cytosine or uracil (C / U), and X +4 When R is a nucleoside other than guanine (G) (R=A, C, or U), translation from the initiation codon is weakly induced, and this is called a "weak" Kozak sequence ((C / U)xxAUGR).
[0049] In one embodiment, when the polypeptide of (B) contains a methionine at position 9 in the amino acid sequence set forth in SEQ ID NO: 1, it is preferable that the Kozak sequence containing the 1st nucleoside of the codon corresponding to the amino acid at position 8 and the 1st nucleoside of the nucleotide encoding the 10th amino acid is "weak." For example, the 9th amino acid in wild-type (WT) AAV6 VP3 is methionine (M211), and its codon is AUG. Furthermore, the 8th amino acid in AAV6 VP3 (WT) is threonine (T210), and its codon is ACx (x is any of uracil, cytosine, adenine, and guanine), and therefore the 1st nucleoside is "A." Furthermore, the amino acid at position 10 in AAV6 VP3 (WT) is alanine (A212), and its codon is GCx, so the nucleoside at position 1 is "G." Therefore, the Kozak sequence containing the codon for methionine at position 9 in AAV6 VP3 is "AcxAUGGcx," which is a "strong" Kozak sequence. For example, in the polypeptide (B) related to AAV6 VP3, if the amino acid at position 8 is substituted from threonine to proline (the codon for which is CCx) (T210P), the Kozak sequence containing the codon for methionine at position 9 in AAV6 VP3 is "CcxAUGGcx," which is a "weak" Kozak sequence. In this example, the VP3 polypeptide (AAV6 VP3(T210P)) of (B) is more preferable than AAV6 VP(WT) from the viewpoint of high gene transfer efficiency (infection efficiency) into mammalian cells by AAV vector particles.
[0050] In the embodiment (A) or (B) above, in which the VP1, VP2, and VP3 polypeptides are encoded by a single gene, amino acids (1st AA or 9th AA) are present at positions corresponding to positions 1 and 9 of the amino acid sequence set forth in SEQ ID NO: 1, and one or both of the 1st AA and 9th AA are methionine, a polypeptide having an amino acid corresponding to a codon that results in a "weak" Kozak sequence including the initiation codon (AUG) that encodes the methionine is preferred from the viewpoint of high gene transfer efficiency (infection efficiency) into mammalian cells by AAV vector particles. In the above example, when either the 1st AA or the 9th AA is methionine, a polypeptide having an amino acid corresponding to a codon that results in a "weak" Kozak sequence including the initiation codon that encodes the methionine is preferred. When both the 1st AA and the 9th AA are methionine, a polypeptide having an amino acid corresponding to a codon that results in a "weak" Kozak sequence including the respective initiation codon that encodes methionine is preferred. It is preferred that only one of the amino acids (1st AA or 9th AA) at positions corresponding to 1 and 9 in the amino acid sequence set forth in SEQ ID NO: 1 is methionine, and that the Kozak sequence including the initiation codon encoding that methionine is "weak."
[0051] The term "sequence identity" refers to the sequence similarity between two optimally aligned polynucleotide sequences or two amino acid strings. If a position in both of the two compared sequences contains the same base or amino acid, the two molecules are identical at that position. The percentage of identity is calculated by dividing the number of identical positions in the two sequences by the total number of positions compared and multiplying the result by 100. Sequence identity can be calculated using commercially or publicly available software, such as BLAST+.
[0052] An amino acid "deletion" means that an amino acid residue is lost at any position in a predetermined amino acid sequence. The amino acid deletion may occur at the N-terminus, C-terminus, and / or any position between the N-terminus and C-terminus of the polypeptide. An amino acid "addition" means that an amino acid residue is added or inserted at any position in a predetermined amino acid sequence. The amino acid addition may occur at the N-terminus, C-terminus, and / or any position between the N-terminus and C-terminus of the polypeptide.
[0053] An amino acid "substitution" refers to the replacement of an amino acid residue at any position in a given amino acid sequence with another amino acid residue. The amino acid substitution may be, for example, a conservative substitution. An amino acid "conservative substitution" refers to the replacement of an amino acid residue in a polypeptide with another amino acid residue from a group of amino acids having similar side chain characteristics (e.g., charge, side chain size, hydrophobicity / hydrophilicity). For example, the group of amino acids having aliphatic side chains consists of glycine, alanine, valine, leucine, and isoleucine; the group of amino acids having aliphatic hydroxyl side chains consists of serine and threonine; the group of amino acids having amide-containing side chains consists of asparagine and glutamine; the group of amino acids having aromatic side chains consists of phenylalanine, tyrosine, and tryptophan; the group of amino acids having basic side chains consists of lysine, arginine, and histidine; the group of amino acids having acidic side chains consists of glutamate and aspartic acid; and the group of amino acids having sulfur-containing side chains consists of cysteine and methionine. Exemplary conservative amino acid substitutions are valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine. Conservative amino acid substitutions in the capsid protein can provide functionally equivalent capsid protein variants.
[0054] The functions of the capsid protein include, for example, the property of forming a capsid, the property of encapsulating a nucleic acid molecule, and / or the property of conferring to the capsid the ability to infect mammalian cells. The capsid protein has, for example, the property of forming a capsid. The capsid protein has, for example, the property of forming a capsid and the property of encapsulating a nucleic acid molecule. The capsid protein has, for example, the property of forming a capsid, the property of encapsulating a nucleic acid molecule, and the property of conferring to the capsid the ability to infect mammalian cells. The polypeptide consisting of the amino acid sequence (B) according to the present disclosure has, for example, the property of forming a capsid.
[0055] In the present disclosure, "VP3 can form a capsid" means that the VP3 has the property of being able to form a capsid alone or together with VP1 and VP2. The capsid may be composed of, for example, VP3, or VP1, VP2, and VP3. Whether an AAV has formed a capsid can be determined by ultracentrifugation analysis. An Optima AUC (Beckman Coulter) ultracentrifuge is used. A sample suspended in a solvent is loaded into a measurement cell. The assembled cell is placed in an AN-50 Ti rotor (Beckman Coulter) and centrifuged at 20,000 rpm and 20°C, and absorbance or interference fringes are detected. The acquired data is analyzed using SEDFIT to determine the sedimentation coefficients of the molecules contained in the sample. When a peak is observed in the estimated sedimentation coefficient of the vector particle, it is determined that a capsid has formed.
[0056] The polypeptide comprising amino acid sequence (B) according to the present disclosure has, for example, the property of forming a capsid, the property of encapsulating a nucleic acid molecule, and / or the property of conferring the ability to infect a mammalian cell to a capsid. The fact that VP3, a polypeptide comprising amino acid sequence (B), has these properties can be confirmed by expressing it together with VP1 and VP2, contacting the produced AAV vector particles with a specific mammalian cell, and then detecting and / or measuring the transcription product and / or translation product of the encapsulated nucleic acid molecule, as shown in the examples of the present disclosure.
[0057] "Sequence identity" refers to the sequence similarity between two optimally aligned polynucleotide sequences or two amino acid strings. If a position in both of the two compared sequences contains the same base or amino acid, the two molecules are identical at that position. The percentage of identity is calculated by dividing the number of identical positions in the two sequences by the total number of positions compared and multiplying by 100. Sequence identity can be calculated using commercially or publicly available software, such as BLAST+.
[0058] The "numbering of amino acid residues" is set by assigning numbers in ascending order from the N-terminus (left end) to the C-terminus (right end) in a specific sequence. For example, in the amino acid sequence set forth in SEQ ID NO: 1, the number 1 is assigned to the methionine (M) at the N-terminus, and the number 533 is assigned to the leucine (L) at the C-terminus.
[0059] In one embodiment, the AAV vector particle comprises a nucleic acid molecule comprising a predetermined nucleotide sequence. The term "nucleic acid molecule" refers to a polymer of nucleotides of any length. Nucleic acid molecules are, for example, ribonucleotides or deoxyribonucleotides. Nucleic acid molecules include, for example, single-stranded, double-stranded, or multi-stranded DNA or RNA, DNA-RNA hybrids, and polymers comprising chemically or biochemically modified non-natural nucleotide bases. Nucleic acid molecules include single-stranded polynucleotides (sense or antisense, etc.) and double-stranded polynucleotides. Nucleic acid molecules comprising a predetermined nucleotide sequence can be prepared, for example, according to known methods (e.g., genetic engineering techniques or chemical synthesis techniques) or are commercially available. The nucleic acid molecule according to the first aspect may be, for example, single-stranded DNA. The AAV vector particle according to the first aspect comprises, for example, single-stranded DNA as the nucleic acid molecule within its internal space.
[0060] The nucleic acid molecule contained in the AAV vector particle contains a "predetermined nucleotide sequence." The predetermined nucleotide sequence is appropriately selected depending on the purpose of using the AAV vector particle. Nucleotide sequences are available, for example, from public institutions (e.g., the National Center for Biotechnology Information (NCBI)). The predetermined nucleotide sequence may be, for example, a sequence encoding a predetermined protein, snRNA, RNAi, or siRNA, or a sequence containing a cloning site for introducing a nucleotide sequence of interest (e.g., a multicloning site sequence).
[0061] Examples of the present disclosure demonstrated that AAV vector particles comprising capsids in which the ratio of the sum of the numbers of VP1 and VP2 to the number of VP3 ([VP1 + VP2] / [VP3]) is 0.3 or greater exhibited improved infection efficiency (see FIG. 12 ). In one embodiment, the capsid protein VP3 is (A) a polypeptide consisting of the amino acid sequence set forth in any one of SEQ ID NOS: 1 to 6 and 25 to 29, wherein the ratio of the sum of the numbers of VP1 and VP2 to the number of VP3 in the AAV capsid ([VP1 + VP2] / [VP3]) is 0.3 or greater (0.32 or greater, 0.34 or greater, or 0.35 or greater). In this embodiment, the VP3 is, for example, a polypeptide consisting of the amino acid sequence set forth in any one of SEQ ID NOS: 1 to 6, or the amino acid sequence set forth in SEQ ID NOS: 1 or 6. The VP3 is preferably a polypeptide consisting of the amino acid sequence set forth in SEQ ID NOS: 1 or 6.
[0062] Regarding the capsid proteins that make up the capsid, the ratio of the number of VP1 and VP2 to the number of VP3 ([VP1 + VP2] / [VP3]) can be measured by the following method. 10Samples containing 1500 ng or 1500 ng of VP1 were prepared. The samples were heat-treated (70°C, 3 minutes) in the presence of SDS and 2-mercaptoethanol (2-ME). The heat-treated samples were buffer-exchanged (into a solution containing 5% 2-ME and 0.475 mg / mL SDS) using an Amicon Ultra-0.5 microcentrifuge tube (30 kD) and then diluted 5-fold with water. The samples were subjected to capillary gel electrophoresis, and the absorbance at 214 nm corresponding to the molecules that had passed through the gel at a certain position was measured. The areas under the curve for the peaks corresponding to VP1, VP2, and VP3 were calculated. The area under the curve for each peak is divided by the molar extinction coefficient of denatured VP at the detected absorbance to determine the number of moles of each VP, and the ratio of the number of VP1 and VP2 to the number of VP3 ([VP1 + VP2] / [VP3]) can be calculated.
[0063] The Examples of the present disclosure demonstrated that the higher the ratio of the number of VP1 and VP2 to the number of VP3, the higher the efficiency of gene transfer (infection efficiency) by AAV vector particles into mammalian cells. The AAV vector particles according to the present disclosure preferably have a ratio of the number of VP1 and VP2 to the number of VP3 of 0.3 or more, preferably 0.32 or more, more preferably 0.34 or more, and even more preferably 0.35 or more. When the AAV capsid contains 60 capsid proteins, [VP1 + VP2] is 13.85 or more, preferably 14.54 or more, more preferably 15.22 or more, and even more preferably 15.55 or more.
[0064] (Nucleic Acid Molecule Comprising a Cap Region) A second aspect of the present disclosure relates to a nucleic acid molecule comprising a polynucleotide sequence encoding VP1, VP2, and VP3. The nucleic acid molecule comprises a polynucleotide sequence encoding VP1, VP2, and VP3, wherein the VP3 is (A) a polypeptide consisting of the amino acid sequence set forth in any one of SEQ ID NOS: 7 to 18; or (B) a polypeptide comprising an amino acid sequence that contains a deletion, substitution, or addition, or a combination thereof, in the amino acid sequence of the polypeptide of (A), and that has at least 80% (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more) sequence identity with the amino acid sequence corresponding to amino acids 18 to 533 of the amino acid sequence set forth in SEQ ID NO: 1, and that is capable of forming the capsid. VP3 according to the second aspect may, for example, comprise the characteristics of VP3 described in the first aspect.
[0065] When VP3 is an mRNA containing a "weak" Kozak sequence, the amount of translated VP3 is lower than when the mRNA contains a mutation that results in the Kozak sequence becoming a "strong" Kozak sequence. When the expression level of VP3 is low, the ratio of the number of VP1 and VP2 to the number of VP3 ([VP1 + VP2] / [VP3]) tends to be high. A high ratio increases the efficiency of gene transfer (infection efficiency) into mammalian cells by AAV vector particles. Therefore, when an amino acid (1st AA or 9th AA) is present at position 1 or 9 of the amino acid sequence set forth in SEQ ID NO: 1, and either or both of the 1st AA and 9th AA are methionine, the Kozak sequence containing the start codon (AUG) encoding the methionine is preferably "weak." When either the 1st AA or 9th AA is methionine, the Kozak sequence containing the start codon encoding the methionine is preferably "weak." When both the 1st AA and the 9th AA are methionine, it is preferred that either one of the Kozak sequences containing the respective initiation codons encoding methionine is "weak", and it is preferred that both of them are "weak".
[0066] In an mRNA encoding wild-type (WT) VP3, both the 1st and 9th AA are methionine, and one or both of the Kozak sequences containing the start codons encoding said methionine are "strong." An mRNA having a mutation introduced to change it to a "weak" Kozak sequence or to replace methionine is preferred. For example, the amino acid sequence of AAV2 VP3 (WT) (SEQ ID NO: 1) contains methionine at both the 1st and 9th AA. The Kozak sequence containing the start codon at the 1st AA (M203) in AAV VP3 (WT) is AcgAUGG, which is "strong." The Kozak sequence containing the start codon at the 9th AA (M211) is CcaAUGG, which is "weak." That is, AAV2 VP3 (WT) contains a methionine in the "strong" Kozak sequence at the 1st AA and a methionine in the "weak" Kozak sequence at the 9th AA (see No. 1 in the "Table" below).
[0067]
[0068]
[0069]
[0070] mRNAs containing a mutation that substitutes the methionine (strong Kozak sequence) at the first AA of AAV2 VP3 (WT) with another amino acid, for example, an mRNA in which a mutation has been introduced into the ACG encoding thymine at position 202 to encode serine (UCG), contain two methionines (M203, M211) at the first and ninth AA, but both of these Kozak sequences are "weak," making them preferable from the viewpoint of gene transfer efficiency (infection efficiency) (see No. 2 in the above "Table"). An mRNA in which a mutation has been introduced into the above mRNA that substitutes M203 with another amino acid, resulting in a single initiation codon (M211 codon), is even more preferable from the viewpoint of gene transfer efficiency (infection efficiency) (see No. 3 in the above "Table"). In another example, mRNAs containing No. 1 in the above Table. In the case of 2, where both the 1st AA and the 9th AA have "weak" methionines, a mutation may be introduced to make one of them a "strong" Kozak sequence (see No. 4 in the Table above). For high gene transfer efficiency (infection efficiency) into mammalian cells by AAV vector particles, nucleic acid molecules containing polynucleotide sequences encoding VP1, VP2, and VP3 into which mutations have been introduced to adjust the strength of the Kozak sequence are preferred. Adjusting the strength of the Kozak sequence for high gene transfer efficiency (infection efficiency) is not limited to mRNA encoding VP3 of AAV2, but can also be similarly performed for VP3 of AAVs of other serotypes.
[0071] The nucleic acid molecule according to the second aspect is, for example, a single-stranded or double-stranded polynucleotide. The nucleic acid molecule is, for example, a double-stranded polynucleotide (e.g., a plasmid). The plasmid includes, for example, a promoter (e.g., a CMV promoter) and an origin of replication.
[0072] The nucleic acid molecule according to the second aspect comprises, for example, a single polynucleotide molecule (single-stranded or double-stranded) comprising a first nucleotide sequence encoding VP1, a second nucleotide sequence encoding VP2, and a third nucleotide sequence encoding VP3. The nucleic acid molecule comprises, for example, a single polynucleotide molecule encoding VP1, VP2, and VP3 in a single gene. When a single gene encodes VP1, VP2, and VP3, these capsid proteins are encoded by a single gene, as in the Cap region of AAV, for example. Preferably, VP1, VP2, and VP3 are encoded by a single gene.
[0073] A third aspect of the present disclosure relates to a kit for preparing AAV vector particles, the kit comprising a first nucleic acid molecule and a second nucleic acid molecule, wherein the first nucleic acid molecule comprises a capsid protein coding region and a Rep region, and the second nucleic acid molecule comprises, in this order (from the 5' end to the 3' end), a first AAV inverted terminal repeat (ITR) sequence, a predetermined nucleotide sequence, and a second AAV-ITR sequence, and the capsid protein coding region comprises a polynucleotide sequence encoding VP1, VP2, and VP3. The VP3 is (A) a polypeptide consisting of the amino acid sequence set forth in any one of SEQ ID NOS: 7 to 18; or (B) a polypeptide consisting of an amino acid sequence which contains a deletion, substitution, or addition, or a combination thereof, in the amino acid sequence of the polypeptide of (A) and which has at least 80% (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more) sequence identity with the amino acid sequence corresponding to amino acids 18 to 533 of the amino acid sequence set forth in SEQ ID NO: 1, and which is capable of forming the capsid. The second nucleic acid molecule comprises, for example, a first AAV-ITR sequence; a promoter; a predetermined nucleotide sequence (e.g., a nucleotide sequence encoding a predetermined protein or a nucleotide sequence containing a multicloning site); and a second AAV-ITR sequence, in this order.
[0074] The term "Rep region" refers to a region encoding proteins involved in AAV replication. The Rep region includes, for example, nucleotide sequences encoding four nonstructural proteins, Rep78, Rep68, Rep52, and Rep40. The amino acid sequences of each of the four nonstructural proteins are available, for example, from public institutions (e.g., NCBI).
[0075] The term "adeno-associated virus-inverted terminal repeat (AAV-ITR) sequence" refers to a sequence capable of forming a hairpin structure that functions as a primer during replication. The AAV-ITR sequence may contribute to packaging of nucleic acid molecules into viral particles. AAV-ITR sequences are available, for example, from public institutions (e.g., NCBI).
[0076] The VP3 according to the third aspect may, for example, include the features of the VP3 described in the first aspect. The capsid protein coding region according to the third aspect may, for example, include the features of the polynucleotide sequence encoding VP1, VP2 and VP3 according to the second aspect.
[0077] The kit may include, for example, a first container containing the first nucleic acid molecule and a second container containing the second nucleic acid molecule. The kit may include the first nucleic acid molecule and the second nucleic acid molecule in a single container. In the kit, the first nucleic acid molecule and the second nucleic acid molecule may be in liquid form, solid (e.g., lyophilized) form, or one may be in liquid form and the other in solid form.
[0078] The kit may further include a third nucleic acid molecule comprising E2A, E4, and VA derived from adenovirus. The third nucleic acid molecule may be, for example, a plasmid or a viral vector. The kit may include, for example, a container containing the first to third nucleic acid molecules in an appropriate combination or separately. The kit may include, for example, the first to third nucleic acid molecules in a liquid or solid state. The kit may include a first container containing the first nucleic acid molecule (preferably a plasmid), a second container containing the second nucleic acid molecule (preferably a plasmid), and a third container containing the third nucleic acid molecule (preferably a plasmid). The first, second, and / or third nucleic acid molecules may be in a solid form, for example, from the viewpoint of storage stability.
[0079] The kit may further include reagents for transfecting the first nucleic acid molecule, the second nucleic acid molecule, and, if present, the third nucleic acid molecule into mammalian cells. The kit may further include instructions for use that describe how to use the kit. The instructions may include, for example, information regarding a predetermined nucleotide sequence of the second nucleic acid molecule (e.g., if the predetermined nucleotide sequence includes a multiple cloning site, sequence information of the nucleotide sequence). The mammalian cells may be, for example, cells derived from a non-human primate such as a chimpanzee, or cells derived from a human.
[0080] The first and second nucleic acid molecules of the kit can be used to prepare predetermined AAV vector particles by transfecting mammalian cells with the above-mentioned third nucleic acid molecule. For example, the transfection is performed at a ratio of the first nucleic acid molecule to the second nucleic acid molecule to the third nucleic acid molecule of 1:1:1. In one embodiment, the kit contains the first nucleic acid molecule, the second nucleic acid molecule, and the third nucleic acid molecule at concentrations and / or amounts suitable for 1:1:1 transfection. The predetermined AAV vector particles can be recovered after production of the AAV vector particles in the transfected mammalian cells.
[0081] (AAV Vector Particle Composition) A fourth aspect of the present disclosure relates to an AAV vector particle composition. The AAV vector particle composition comprises an AAV vector particle according to the present disclosure. The AAV vector particle composition may comprise, for example, empty capsids in addition to complete particles, intermediate particles, or nucleocapsids. The AAV vector particle composition comprises AAV vector particles at a ratio of, for example, 50% or more (e.g., 60% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100%) relative to the total moles of capsids.
[0082] An AAV vector particle according to the present disclosure comprises a capsid, the capsid comprising VP1, VP2, and VP3, wherein the VP3 is (A) a polypeptide consisting of an amino acid sequence set forth in any one of SEQ ID NOS: 1 to 6 and 25 to 29; or (B) an amino acid sequence comprising a deletion, substitution, or addition, or a combination thereof, in the amino acid sequence of the polypeptide of (A), and having at least 80% sequence identity with the amino acid sequence corresponding to positions 18 to 533 of the amino acid sequence set forth in SEQ ID NO: 1, and When the capsid is a polypeptide capable of forming the capsid, and the ratio of the number of VP1 and VP2 to the number of VP3 in the capsid ([VP1+VP2] / [VP3]) is 0.3 or more, the AAV vector particle composition contains the AAV vector particles at a ratio of, for example, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 99% or more, or 100% relative to the total number of moles of the capsid.
[0083] When the AAV vector particle according to the present disclosure comprises a capsid, the capsid comprises VP3, and the VP3 is (A) a polypeptide consisting of the amino acid sequence set forth in any of SEQ ID NOs: 7 to 18; or (B) a polypeptide that contains a deletion, substitution, or addition, or a combination thereof, in the amino acid sequence of the polypeptide of (A) and that consists of an amino acid sequence that has at least 80% sequence identity with the amino acid sequence corresponding to amino acids 18 to 533 of the amino acid sequence set forth in SEQ ID NO: 1, and is capable of forming the capsid, the AAV vector particle composition comprises the AAV vector particles at a ratio of, for example, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100% relative to the total molar number of the capsid.
[0084] The AAV vector particle composition contains AAV vector particles in which the ratio of the number of VP1 and VP2 to the number of VP3 in the capsid ([VP1+VP2] / [VP3]) is 0.3 or more (preferably 0.32 or more, more preferably 0.34 or more, and even more preferably 0.35 or more), relative to the total number of moles of capsids, in an amount of 50% or more (preferably 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more).
[0085] The AAV vector particle composition can be produced, for example, by the ultracentrifugation method described in the embodiments of the present disclosure. For example, the ultracentrifugation method involves suspending a sample that may contain AAV vector particles in a solution containing cesium chloride, and subjecting the suspension to ultracentrifugation at 60,000 to 240,000 × g for 3 to 72 hours, thereby separating the sample into layers containing predetermined AAV vector particles. The separated layers can be fractionated according to known methods. The separated layers can be fractionated using a commercially available fractionator (TRIAX GRADIENT PROFILING SYSTEM (SK Bio International Co., Ltd.)). The solvent in the fractionated AAV vector particle composition may be replaced with a desired solvent, for example, by dialysis. The fractionated AAV vector particle composition may be further purified (e.g., ultracentrifugation), for example, to increase the ratio of AAV particles to capsid particles. The AAV vector particles are preferably prepared using mammalian cells (adherent cells or suspension cells) and are preferably purified by affinity chromatography.
[0086] The "proportion (%) of AAV vector particles to the total number of moles of capsids" can be calculated by subjecting a target AAV vector particle composition (in a non-denatured state) to capillary gel electrophoresis and measuring the absorbance value at 214 nm corresponding to molecules that have passed through a certain position during electrophoresis. In the measured absorbance, the total area of the peaks corresponding to capsid particles (e.g., hollow particles, complete particles, intermediate particles, or nucleocapsids) (corresponding to the total number of moles of capsids) and the area of the peak corresponding to the target AAV vector particles (corresponding to the number of target AAV vector particles) are measured. The percentage can be obtained by dividing the area of the latter by the total area of the former and multiplying by 100.
[0087] The AAV vector particle composition can be used as a pharmaceutical composition, as described below. The AAV vector particle composition can also be used for introducing genes into mammalian cells in vitro, as described below. The composition comprising the AAV vector particles of the present disclosure can improve the efficiency of introducing genes carried by the AAV vector, for example, by improving the infection efficiency of mammalian cells.
[0088] (Pharmaceutical Composition) A fifth aspect of the present disclosure relates to a pharmaceutical composition. The pharmaceutical composition comprises an AAV vector particle or an AAV vector particle composition according to the present disclosure. The pharmaceutical composition may further comprise, for example, a carrier, a preservative, a chemical stabilizer, or a known pharmaceutical ingredient. For example, the pharmaceutical composition comprises an AAV vector particle or an AAV vector particle composition according to the present disclosure and a carrier.
[0089] The carrier may be appropriately selected depending on, for example, the route of administration of the pharmaceutical composition. Examples of the carrier include a buffer solution (e.g., phosphate buffered saline), saline, lactose, sucrose, calcium phosphate, gelatin, dextran, or water. Examples of the preservative include sorbic acid, paraben, ethyl vanillin, glycerin, or parachlorophenol. Examples of the chemical stabilizer include gelatin or albumin.
[0090] The pharmaceutical compositions can be administered systemically or locally, depending on the purpose, for example, orally, by inhalation (e.g., intranasal and intratracheal delivery), intraocularly, intravenously, intramuscularly, subcutaneously, intradermally, or intratumorally.
[0091] The pharmaceutical composition can be produced according to a known method, for example, by mixing the AAV vector particles or AAV vector particle composition according to the present disclosure with a carrier.
[0092] Another aspect of the present disclosure relates to a method of treatment comprising administering a pharmaceutical composition according to the present disclosure to a human subject in need thereof to treat a disease or disorder, where "treatment" includes maintaining, reducing, or eliminating the symptoms or pathology.
[0093] A sixth aspect of the present disclosure relates to an in vitro method for causing transcription and / or expression of a predetermined nucleotide sequence in a mammalian cell, the in vitro method comprising contacting a mammalian cell with an AAV vector particle or AAV vector particle composition according to the present disclosure, and placing the cell under conditions that allow for the transcription and / or expression of the predetermined nucleotide sequence.
[0094] Contacting mammalian cells with the AAV vector particles or AAV vector particle composition of the present disclosure includes, for example, adding the AAV vector particles or AAV vector particle composition to a culture medium containing mammalian cells. For example, the AAV vector particles of the present disclosure can infect mammalian cells and introduce nucleic acid molecules carried by the AAV vector particles into the mammalian cells.
[0095] Placing the mammalian cells into which the predetermined nucleotide sequence has been introduced under conditions that allow transcription and / or expression of the predetermined nucleotide sequence can be carried out, for example, under conditions suitable for the growth of the mammalian cells (e.g., at 37°C and 5% CO 2 ) including maintaining it at
[0096] The mammalian cells induced to transcribe and / or express the selected nucleotide sequence in vitro can be administered to a mammal in need thereof, for example, the mammalian cells can be cells of non-human primate origin, such as a chimpanzee, or cells of human origin.
[0097] As used herein, the term "comprising" means that the recited elements and / or steps are present, and that other elements and / or steps may be added. As used herein, the term "consisting of" means that the recited elements and / or steps are present, but that other corresponding elements and / or steps are excluded. For example, if a certain element (e.g., a buffer) is specified as "consisting of phosphate," this means that the phosphate is present (as a buffer), but that other corresponding elements (buffers other than phosphate) are excluded. As used herein, the term "essentially consisting of" means that the recited elements and / or steps are present, and that other corresponding elements and / or steps may be added to the extent that they do not affect the novel technical features of the AAV vector particles, compositions, and methods. As used herein, the term "substantially free" does not exclude "completely free."
[0098] The terms and embodiment descriptions provided by this disclosure apply appropriately among the aspects and embodiments provided by this disclosure unless otherwise specified.
[0099] Specific examples will be described below, but these are intended to illustrate preferred embodiments of the invention according to the present disclosure and are not intended to limit the invention described in the appended claims in any way.
[0100] Example 1 (1) Preparation of Recombinant Adeno-Associated Virus (rAAV) The RepCap plasmid, which contains the AAV Rep and Cap genes, the pHelper plasmid, which contains the adenovirus helper gene, and the GOI plasmid, which contains a transgene and an EGFP gene downstream of a CMV promoter, were prepared. The three plasmids were transfected into suspension HEK293T cells or Vpc2.0 cells (Thermo Fisher) at a 1:1:1 ratio. Transfection was performed using PEIpro® or FectoVIR (both Polypuls) according to the Polypuls recommended protocol.
[0101] After transfection, the cells were incubated with sodium bicarbonate (Fujifilm Wako Pure Chemical Industries, Ltd.) and L-glutamine (Fujifilm Wako Pure Chemical Industries, Ltd.) in Balan CD (Fujifilm Wako Pure Chemical Industries, Ltd.) at 37°C and 8% CO 2 The cells were cultured at 4°C for 2 to 4 days. For serotypes in which the formed virus particles are released extracellularly, the virus particles were collected from the culture supernatant. For serotypes in which the formed virus particles are maintained intracellularly, the virus particles were collected from a cell lysate obtained by lysing the cultured cells. Cell lysis was performed using AAV-Max Lysis Buffer (Thermo Fisher).
[0102] Recovery (rough purification) of virus particles was carried out by affinity chromatography. TM GoPure TM An AKTA avant (Cytiva) equipped with an AAVX Pre-packed Column (0.8 x 10 cm, 5 mL (Thermo Fisher)) was used. Crude purification of virus particles was carried out according to the recommended protocol for the column.
[0103] (2) Purification of rAAV particles by ultracentrifugation. The crudely purified rAAV particles were suspended in 2.5 M CsCl / PBS containing 0.001 w / v% poloxamer-188 solution in a 13.2 mL ultra-clear ultracentrifuge tube to a final volume of 12 mL. The tube was then subjected to ultracentrifugation at 34,000 rpm (197,910 x g) at 20°C for 72 hours in an Optima XE-90 (Beckman Coulter) equipped with a Beckman SW41Ti rotor (see Figure 1A).
[0104] Figure 1A shows that crudely purified rAAV serotype 2 (also referred to as "AAV2" or "type 2 AAV") particles were separated into two bands (Empty band and Bulk band). The Empty band was subjected to electrophoresis and absorbance measurement. The results revealed that the Empty band contained protein but no DNA. This result suggests that the Empty band is an rAAV2 capsid containing capsid proteins but no genomic DNA (also referred to as "empty particles"). The results of electrophoresis and absorbance measurement of the Bulk band revealed that the Bulk band contained protein and DNA. This result suggests that the Bulk band is an rAAV2 capsid containing genomic DNA as well as capsid proteins (also referred to as "complete particles"). Figure 1A shows that the Bulk band can be further separated into two bands (F1 band and F2 band).
[0105] Figure 1A shows a white layer below the bulk band. This white layer was subjected to electrophoresis and absorbance measurement. The results revealed that the white layer contained neither protein nor DNA. Considering this result and the cesium chloride density value, this white layer is suggested to be precipitated cesium chloride.
[0106] (3) Further Purification of rAAV Particles after Ultracentrifugation The F1 and F2 bands shown in Figure 1A were collected and further characterized. The collected rAAV2 particles corresponding to the F1 band were suspended in 2.5 M CsCl / PBS containing 0.001 w / v% poloxamer-188 solution. The suspension was subjected to ultracentrifugation at 24,000 rpm (98,612 x g) for 72 hours (Figure 1B). The collected rAAV2 particles corresponding to the F2 band were also subjected to ultracentrifugation in the same manner (Figure 1C). Figure 1B shows that the rAAV2 particles corresponding to the F1 band were further separated into relatively low-density virus particles (F1.1 band) and relatively high-density virus particles (F1.2 band). Figure 1C shows that the rAAV2 particles corresponding to the F2 band were relatively high-density virus particles (F2.2 band).
[0107] (4) Capillary gel electrophoresis of F1.1 band and F2.2 band The bulk band after ultracentrifugation and the F1.1 band and F2.2 band after two rounds of ultracentrifugation were each subjected to a fractionator (TRIAX GRADIENT PROFILING SYSTEM (SK Bio International Co., Ltd.)) to obtain fractions containing virus particles, which were then dialyzed (PBS / 0.001% w / v). Virus particles were recovered from the dialyzed fractions and subjected to capillary gel electrophoresis (Figure 2). A PA800 plus (Sciex) capillary gel electrophoresis apparatus was used.
[0108] In the bulk band, three peaks were observed with radii (cm) near 6.25, 6.7, and 6.9 (Figure 2A). Taking into account the results in Figure 1A, the peak with a radius (cm) near 6.7 is thought to contain relatively low-density rAAV2 particles corresponding to the F1 band observed in Figure 1A, while the peak with a radius of near 6.9 is thought to contain relatively high-density rAAV2 particles corresponding to the F2 band observed in Figure 1A. The area under the curve for each peak observed in Figure 2A reflects the amount (number of moles) of rAAV2 particles corresponding to that peak. Figure 2A shows that the bulk band contains a small amount of relatively low-density rAAV2 particles (peak with a radius (cm) near 6.7) and a large amount of relatively high-density rAAV2 particles (peak with a radius (cm) near 6.9).
[0109] In the F1.1 band, two peaks were observed, with radii (cm) near 6.7 and 6.9 (Figure 2B). Taking into account the results in Figure 1B, the peak with a radius (cm) near 6.7 is thought to contain relatively high-density rAAV2 particles corresponding to the F1.1 band observed in Figure 1B, while the peak with a radius (cm) near 6.9 is thought to contain relatively low-density rAAV2 particles corresponding to the F1.2 band observed in Figure 1B. Figure 2B shows that the F1.1 band contains a large amount of relatively low-density rAAV2 particles (peak with a radius (cm) near 6.7) and a small amount of relatively high-density rAAV2 particles (peak with a radius (cm) near 6.9).
[0110] In the F2.2 band, a single peak was observed at a radius (cm) of approximately 6.9 (Fig. 2C). Considering the results in Fig. 1C, the peak at a radius (cm) of approximately 6.9 indicates that it contains a relatively high density of rAAV2 particles at high purity, corresponding to the F2.2 band observed in Fig. 1C.
[0111] Considering the results in Figure 2B and Figure 2C, the rAAV2 particles that showed a peak at around 6.9 in capillary gel electrophoresis for F1 (corresponding to the F1.2 band) and the rAAV2 particles that showed a peak at around 6.9 in capillary gel electrophoresis for F2 (corresponding to the F2.2 band) are thought to be the same rAAV2 particles. Further analysis will be performed on the rAAV2 particles in the F1.1 band and the F2.2 band below.
[0112] (5) Further Characterization of rAAV2 Particles The relatively low-density rAAV2 particles and the relatively high-density rAAV2 particles were further characterized. (5-1) Density Difference From the results in Figure 2, the difference between the estimated density of the relatively low-density rAAV2 particles corresponding to the F1.1 band in Figure 1B and the estimated density of the relatively high-density rAAV2 particles corresponding to the F2.2 band in Figure 1C was approximately 0.009 g / cm 3 It was shown that...
[0113] (5-2) Sedimentation Coefficient The sedimentation coefficient of the relatively low-density rAAV2 particles corresponding to the F1.1 band in Figure 1B was 99.5 (S) (Figure 3A), and the sedimentation coefficient of the relatively high-density rAAV2 particles corresponding to the F2.2 band in Figure 1C was 97.2 (S) (Figure 3B). Considering that the AAV2 capsid is composed of 60 copies of capsid protein and that the length of DNA encapsulated in the relatively low-density rAAV2 particles and the relatively high-density rAAV2 particles is the same, these differences in density and sedimentation coefficient were thought to be due to changes in the composition ratio of the capsid proteins that make up the capsid.
[0114] (5-3) Capsid Protein Composition Ratio rAAV2 particles corresponding to the F1.1 band were heat-treated (70°C, 3 minutes) in the presence of SDS and 2-mercaptoethanol (2-ME) and subjected to capillary gel electrophoresis. A PA800 plus (Sciex) capillary gel electrophoresis apparatus was used. The electrophoresis samples were detected using a PDA detector (absorption wavelength 214 nm). As a result of electrophoresis, absorbance peaks corresponding to each capsid protein were observed. The area under the curve of the observed peak reflects the amount (moles) of capsid protein that represented that peak. The ratio of the peak area (moles) of each capsid protein to the peak area (moles) corresponding to capsid protein VP1 (VP ratio) was calculated (see F1.1 in Figure 4).
[0115] The rAAV2 particles corresponding to the F2.2 band and the rAAV2 particles corresponding to the Bulk band were also subjected to capillary gel electrophoresis in the same manner as for F1.1 above, and the proportion of each capsid protein was calculated (see F2.2 and Bulk in Figure 4).
[0116] 4 shows that the capsid of rAAV2 particles corresponding to the F1.1 band has a decreased proportion of [VP3 + VP3 clip] (particularly the proportion of VP3) and an increased proportion of [VP1 + VP2] compared to the capsid of rAAV2 particles corresponding to the F2.2 band. The molecular weight of VP1 of the rAAV2 particle is 81.9 kDa, the molecular weight of VP2 is 66.5 kDa, the molecular weight of VP3 is 60.0 kDa, and the molecular weight of the VP3 clip is 59.9 kDa (Non-Patent Document 1). VP3 is a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 1, and the VP3 clip is a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 7.
[0117] Considering the molecular weight of the capsid protein as described above, Figure 4 suggests that the rAAV2 particles corresponding to the F1.1 band have a larger molecular weight than the capsid of the rAAV2 particles corresponding to the F2.2 band, as a result of an increased proportion of [VP1 + VP2], which has a relatively large molecular weight. Furthermore, considering that the capsid is composed of 60 copies of capsid protein, the rAAV2 particles corresponding to the F1.1 band are presumed to be of similar size to the capsid of the rAAV2 particles corresponding to the F2.2 band. Furthermore, the density of the rAAV2 particles is the average value of the density of the capsid protein and the density of the encapsulated DNA, and the density of the capsid protein (1.3 g / cm 3 ) is the density of DNA (1.5 g / cm 3 ) Taking all these factors into consideration, Figure 4 suggests that the rAAV2 particles corresponding to the F1.1 band have an increased proportion of capsid protein, resulting in a decreased density compared to the capsid of the rAAV2 particles corresponding to the F2.2 band.
[0118] The suggestion that rAAV2 particles corresponding to the F1.1 band have a lower density than rAAV2 particles corresponding to the F2.2 band is consistent with the estimated density results shown in (5-1) of Example 1. Furthermore, the suggestion that rAAV2 particles corresponding to the F1.1 band have a larger molecular weight than rAAV2 particles corresponding to the F2.2 band and that the sizes of these virus particles are similar is consistent with the sedimentation coefficient results shown in (5-2) of Example 1. These results support the idea that the proportion of [VP1+VP2] constituting the capsid of rAAV2 particles corresponding to the F1.1 band increased, resulting in an increase in molecular weight without a change in size.
[0119] (5-4) Gene transfer efficiency into cells: 8 x 10 4HeLa RC32 cells (100, 500, 1000, 2500, and 5000 times the viral load (MOI: multiplicity of infection) were infected into 100 cells / well. Cells infected with rAAV2 particles corresponding to the F1.1 band were subjected to a flow cytometer. The EGFP gene (GOI gene) was introduced into the flow cytometer, and the number of cells expressing EGFP was counted. The gene transfer efficiency was calculated by calculating the number of cells expressing EGFP relative to the number of cells subjected to the flow cytometer (see circles in Figure 5). The gene transfer efficiency was also calculated in the same manner for rAAV2 particles corresponding to the F2.2 band (see triangles in Figure 5). Figure 5 shows that the gene transfer efficiency of rAAV2 particles corresponding to the F1.1 band was higher than that of rAAV2 particles corresponding to the F2.2 band.
[0120] Example 1 demonstrated that when wild-type rAAV2 was prepared in vitro, at least two particle species were present in the complete particles (see Figures 1 and 2). It also demonstrated that there was a difference in the proportion of capsid proteins constituting the capsid between the two AAV2 particle species (see Figure 4). Furthermore, it was demonstrated that the relatively low-density rAAV2 particle species (rAAV2 present in the F1.1 band) had a higher gene transfer efficiency than the relatively high-density rAAV2 particle species (rAAV2 present in the F2.2 band) (see Figure 5). Since the difference between the relatively high-density rAAV2 particle species and the relatively low-density rAAV2 particle species was the proportion of capsid proteins, it is unlikely that there was a difference in the process from gene transfer into cells to EGFP expression. Therefore, the increase in gene transfer efficiency is thought to be due to the fact that relatively low-density rAAV2 particle species have a higher cell infection efficiency than relatively high-density rAAV2 particle species.
[0121] [Example 2] (1) Preparation of VP3-modified recombinant AAV variants (1-1) Preparation of polynucleotides encoding AAV2 VP3 variants Variants of AAV2 VP3 exist (Non-Patent Document 1). This is thought to be due to the presence of another methionine near the start codon (methionine) present at the N-terminus of VP3. The AAV capsid proteins VP1, VP2, and VP3 are encoded by a single gene (Cap region) with their C-terminal regions overlapping. VP1, VP2, and VP3 differ in the position of the start codon (methionine) within a single gene in the Cap region.
[0122] The start codon (methionine) of VP3 corresponds to position 203 of VP1 when VP1 and VP3 are aligned, for example. Herein, the start codon (methionine) of VP3 is also referred to as "M203." Another methionine present near the start codon (M203) of VP3 corresponds to position 211 of VP1 (corresponding to methionine at position 9 in the amino acid sequence set forth in SEQ ID NO: 1). This other methionine is also referred to as "M211." The C-terminus of VP3 corresponds to position 735 of VP1. Wild-type (WT) VP3 of AAV2 has M203 at its N-terminus and is 533 amino acids long, and its sequence is publicly available, for example, from the National Center for Biotechnology Information under accession number "P03135" (SEQ ID NO: 1). The above-mentioned VP3 variant (VP3 clip) has M211 at the N-terminus and is 525 amino acids long (see the amino acid sequence set forth in SEQ ID NO: 7).
[0123] A polynucleotide was prepared encoding the M203V-AAV2 VP3 variant (SEQ ID NO: 19), in which methionine (M) at position 1 ("M203") in AAV2 WT VP3 (SEQ ID NO: 1) was substituted with valine (V). This polynucleotide is expected to produce the M203-AAV2 VP3 variant consisting of the amino acid sequence set forth in SEQ ID NO: 7 (corresponding to the VP3 clip). Furthermore, a polynucleotide was prepared encoding the M211V-AAV2 VP3 variant (SEQ ID NO: 8), in which methionine (M211) at position 9 in AAV2 WT VP3 (SEQ ID NO: 1) was substituted with valine (V).
[0124] The table below compares the amino acid sequences of positions 1 to 10 (positions 203 to 212 in the amino acid sequence of VP1) of WT-AAV2 VP3 (SEQ ID NO: 1), M203V-AAV2 VP3 (SEQ ID NO: 7), and M211V-AAV2 VP3 (SEQ ID NO: 8).
[0125] Furthermore, a polynucleotide encoding VP3 in which methionine at position 9 (M211) in AAV2 WT VP3 (SEQ ID NO: 1) was substituted with alanine (also referred to as "M211A-AAV2 VP3") was prepared. Furthermore, a polynucleotide encoding VP3 in which both M203 and M211 were substituted with valine (also referred to as "M203,M211V-AAV2 VP3") was prepared.
[0126] (1-2) Preparation of Polynucleotides Encoding AAV8 VP3 Variants A polynucleotide encoding a VP3 (also referred to as "M203V-AAV8 VP3") in which methionine at position 1 (M203) in wild-type VP3 of VV8 (SEQ ID NO: 6) was substituted with valine was prepared. In addition, a polynucleotide encoding a VP3 (also referred to as "M211V-AAV8 VP3") in which M211 was substituted with valine was prepared.
[0127] (1-3) Preparation of rAAV2 Variant The M203V-rAAV2 variant was prepared by producing the M203V-AAV2 VP3 prepared above together with AAV2 VP1 and VP2 in the same manner as in (1) to (3) of Example 1. Similarly, the M211V-rAAV2 variant was prepared using the M211V-AAV2 VP3. The capsid of the M203V-rAAV2 variant is expected to be composed of VP1, VP2, and the VP3 clip (SEQ ID NO: 7) without containing wild-type (WT) VP3 (533 amino acids long: SEQ ID NO: 1). The M211V-rAAV2 variant capsid is expected to lack the VP3 clip (525 amino acids long) and be composed of VP1, VP2, and a 533 amino acid VP3 variant corresponding to WT-VP3. Furthermore, the M211A-rAAV2 variant was prepared using the M211A-AAV2 VP3; and the M203,211V-rAAV2 variant was prepared using the M203,211V-AAV2 VP3.
[0128] The prepared AAV2 variants were examined for viral titer (Figure 6). The viral titer was measured by quantifying the viral (AAV) inverted terminal repeat (ITR) sequence contained in each AAV2 variant using quantitative PCR (qPCR) or digital PCR (dPCR). The negative control shows the results when a plasmid containing a transgene was transfected (residual plasmid). Figure 6 shows that rAAV2 (WT) prepared using wild-type VP3 had a viral titer of approximately 7.5 x 10 10 (vg / ml). Both the M203V-rAAV2 variant and the M211V-rAAV2 variant showed titers identical to those of WT-rAAV2 (see "M203V" and "M211V" in Figure 6). Figure 6 also shows that the M211A-rAAV2 variant and the M203,211V-rAAV2 variant both showed values similar to the viral titer of the negative control and did not show significant viral titers (see "M211A," "M203,211V," and "Negative control" in Figure 6). These results suggest that the M203V-rAAV2 variant and the M211V-rAAV2 variant formed viral particles. On the other hand, this suggests that the M211A-rAAV2 variant and the M203,211V-rAAV2 variant did not form virus particles.
[0129] The M203L-rAAV2 variant, prepared by producing AAV2 WT VP3 (SEQ ID NO: 1) in which methionine at position 1 (M203) was substituted with leucine (also referred to as "M203L-AAV2 VP3") together with AAV2 VP1 and VP3, does not form virus particles (Non-Patent Document 1). Furthermore, the M211L-rAAV2 variant, prepared using VP3 in which M211 was substituted with leucine (also referred to as "M211L-AAV2 VP3"), also does not form virus particles (Non-Patent Document 1).
[0130] (1-4) Preparation of rAAV8 Variants Furthermore, M203V-rAAV8 VP3 was produced together with AAV8 VP1 and VP2 to prepare M203V-rAAV8 variants. Similarly, M211V-rAAV8 variants were prepared using M211V-AAV8 VP3. Furthermore, the viral titers of these rAAV8 variants were measured in the same manner as in (1-3) of Example 2. The results suggested that the M203V-rAAV8 variant and M211V-rAAV8 variant formed viral particles.
[0131] (2) Density of rAAV2 Variant Particles The rAAV2 variants that were shown to form viral particles, specifically the M203V-rAAV2 variant and the M211V-rAAV2 variant, were further characterized below. Purified rAAV2 variant particles and wild-type (WT) rAAV2 particles were subjected to capillary gel electrophoresis in the same manner as in (4) of Example 1 (see Figures 7A to 7C). Figure 7A shows a peak corresponding to relatively low-density rAAV2 particles (Radius (cm) around 6.7) and a peak corresponding to relatively high-density rAAV2 particles (Radius (cm) greater than 6.9), as observed in Example 1 (see Figure 2A). Figure 7A also shows a heterogeneous mixture, with the majority of particles being relatively high-density WT-rAAV2 particles. In Figure 7B, a single peak was observed at a radius (cm) smaller than 6.9. In Figure 7C, a single peak was also observed at a radius (cm) smaller than 6.9. These results indicate that the rAAV2 variants produced (Figures 7B and 7C) were a relatively lower density and more homogeneous population of AAV2 particles than the rAAV2 particles corresponding to the peak observed at a radius (cm) greater than 6.9 (Figure 7A).
[0132] (3) Mass of rAAV2 Variant Particles The masses of the purified rAAV2 particles were measured by charge detection mass spectrometry (CD-MS) (Figures 7D-7E). Figure 7D shows that WT-rAAV2 particles are approximately 4.478 MDa. Figure 7E shows that M203V-rAAV2 variant particles are approximately 4.487 MDa. Figure 7F shows that M211V-rAAV2 variant particles are approximately 4.478 MDa. These results indicate that the prepared rAAV2 variant particles have a larger mass than WT-rAAV2 particles.
[0133] In Example 2(2), capillary gel electrophoresis was performed to demonstrate that the density of rAAV2 variant particles was lower than that of WT-rAAV2 particles (which accounted for the majority of rAAV2 particles with a relatively high density). The capsid sizes were approximately the same (composed of 60 copies of capsid protein), and the density of rAAV2 particles was the average of the density of the capsid protein and the density of the encapsulated DNA, and the density of the capsid protein (1.3 g / cm) was 1.3 g / cm. 3 ) is the density of DNA (1.5 g / cm 3 Considering that the mass of rAAV2 variant particles is smaller than that of WT-rAAV2 particles, the results of capillary gel electrophoresis suggest that the mass of rAAV2 variant particles is larger than that of the relatively dense WT-rAAV2 particles. This suggestion is consistent with the results shown by CD-MS in Example 2(3).
[0134] (4) Capsid Proteins of rAAV2 Variant Particles The capsid protein composition of purified rAAV2 variants was investigated in the same manner as in (5-3) of Example 1. Figures 8A to 8C show the absorbance measurement results of capillary gel electrophoresis of each rAAV2 particle after heat treatment (70°C, 3 minutes) in the presence of SDS and 2-ME. Figure 8A shows that wild-type (WT) AAV2 capsids are composed of VP1, VP2, VP3, and the VP3 clip. WT-AAV2 capsids contain a significantly higher amount of VP3 than the VP3 clip. Figure 8B shows that the capsid of the M203V-AAV2 variant is composed of VP1, VP2, VP3, and the VP3 clip. As expected, the M203V-AAV2 variant, unlike WT-AAV2, contained a large amount of the VP3 clip. Unexpectedly, the capsid of the M203V-AAV2 variant contained a small amount of VP3. Figure 8C shows that the capsid of the M211V-AAV2 variant is composed of VP1, VP2, and VP3. As expected, the capsid of the M211V-AAV2 variant did not contain the VP3 clip.
[0135] (5) Capsid Proteins VP3 and VP3 Clip of rAAV2 Variant Particles The masses of VP3 and VP3 clip of WT-rAAV2 particles and rAAV2 variant particles were analyzed by mass spectrometry (Figures 8D-8F). rAAV samples were denatured with 10% acetic acid (Fujifilm Wako Chemicals) and incubated at room temperature for 15 minutes. For on-column denaturation, rAAV samples were used directly without acetic acid treatment. AAV samples were injected into a Nexra HPLC (Shimadzu, Kyoto, Japan) coupled to a maXis II ETD ESI-QTOF mass spectrometer (Bruker). Separation of the capsid proteins VP1, VP2, and VP3 was performed on an ACQUITY BEH C4 column (300A, 1.7 μm, 2.1 mm x 150 mm, Waters, Milford, MA) at a flow rate of 0.2 mL / min and a temperature of 80°C. Mobile phases A and B were 0.1% difluoroacetic acid (Waters) in MS-grade water (Kanto Chemical Co., Tokyo, Japan) and acetonitrile (Thermo Fisher Scientific), respectively. The pH values of solution A and the mixture of 95% solution A and 5% solution B were 1.93 and 1.90, respectively. Intact VP was eluted from a gradient of 32% B to 36% B in 15 minutes. LC chromatograms were detected using ultraviolet absorption at an excitation wavelength of 280 nm and an emission wavelength of 350 nm, as well as the intrinsic fluorescence of aromatic amino acids. Deconvolution analysis was performed in the mass range of 40,000-90,000 Da to determine the mass values of the VP components contained in the elution peaks. Mass spectra were visualized and processed using Bruker Compass Data Analysis software version 5.1 (Bruker), and Maximum Entropy was used for deconvolution.
[0136] Figure 8D shows that the VP3 mass of WT-rAAV2 particles is approximately 59.97 kDa and the VP3 clip mass is approximately 59.30 kDa. Figure 8E shows that the VP3 mass of M203V-rAAV2 variant particles is approximately 59.97 kDa and the VP3 clip mass is approximately 59.3 kDa. Figure 8F shows that the VP3 mass of M211V-rAAV2 variant particles is approximately 59.94 kDa. These results indicated that a specific VP3 and / or VP3 clip was produced in each rAAV2.
[0137] (6) Capsid Protein Composition Ratio in rAAV2 Variant Particles The VP ratio (corresponding to the ratio in number) of the peak area of each capsid protein was calculated based on the peak area (corresponding to the number of moles) corresponding to capsid protein VP1 from Figures 8A to 8C (Figure 9). Unexpectedly, the M203V-AAV2 variant had a reduced ratio of [VP3 + VP3 clip] compared to WT-AAV2. The M211V-AAV2 variant also had a reduced ratio of [VP3 + VP3 clip] compared to WT-AAV2.
[0138] (7) Gene Transfer Efficiency (Infection Efficiency) into Cells by rAAV2 Variant Particles Cells were infected with rAAV2 variants in the same manner as in (5-4) of Example 1, and the transfer efficiency (infection efficiency) of the EGFP gene was examined ( FIG. 10 ). FIG. 10( a) shows the infection efficiency of HeLa RC32 cells, indicating that the M203V-rAAV2 variant (●) had a higher infection efficiency than the WT-rAAV2 (■) and M211V-rAAV2 variant (▲). It also shows that the M211V-rAAV2 variant (▲) had a higher infection efficiency than the WT-rAAV2 (■). Figure 10(b) shows the infection efficiency of HEK293T cells, demonstrating that the M203V-rAAV2 variant (●) had a higher infection efficiency than the WT-rAAV2 (■) and M211V-rAAV2 variant (▲). Furthermore, the M211V-rAAV2 variant (▲) had a higher infection efficiency than the WT-rAAV2 (■) at a relatively low MOI (up to 500). Figure 10(c) shows the results of examining the infection efficiency of HeLa RC32 cells using a different lot of rAAV2 particles prepared separately from the rAAV2 particles used in Figure 10(a). Figure 10(c) reproduces the results seen in Figure 10(a). This result demonstrates that the infection efficiency of various rAAV2s in cells is reproducible, regardless of the rAAV2 production lot.
[0139] (8) Relationship between Capsid Protein Proportions and Gene Transfer Efficiency (Infection Efficiency) From the capsid protein proportions for each rAAV2 obtained in (5-3) of Example 1 and (6) of Example 2, the ratio of the combined proportions of the capsid proteins VP1 and VP2, which have relatively large molecular weights, to the combined proportions of the capsid proteins VP3 and VP3 clip, which have relatively small molecular weights, ([VP1 + VP2] / [VP3 + VP3 clip]) was calculated ( FIG. 11A ). The calculated ratios are summarized in the following table.
[0140]
[0141] For rAAV2 particles corresponding to the WT-rAAV2 Bulk band (see Figure 1A), the ratio of [VP1 + VP2] / [VP3 + VP3 clip] was 0.282. The [VP1 + VP2] / [VP3 + VP3 clip] ratio per 60 copies constituting the AAV2 capsid was 13.2 and 46.8, respectively. The ratio of [VP1 + VP2] / [VP3 + VP3 clip] for rAAV2 particles corresponding to the WT-rAAV2 F1.1 band (see Figure 1B) (WT(F1.1)) was higher than that for rAAV2 particles corresponding to the WT-rAAV2 F2.2 band (see Figure 1C) (WT(F2.2)) (0.310 vs. 0.266). The M203V-rAAV2 variant particles and M211V-rAAV2 variant particles had a higher [VP1 + VP2] / [VP3 + VP3 clip] ratio than the WT-rAAV2 particles corresponding to the F1.1 band (WT(F1.1)) (0.351 or 0.322 vs. 0.310).
[0142] WT-rAAV2 particles corresponding to the F1.1 band (WT(F1.1)), which had a higher ratio of [VP1+VP2] / [VP3+VP3 clip] than WT-rAAV2 particles corresponding to the F2.2 band (WT(F2.2)), also had a higher gene transfer efficiency (infection efficiency) (see Example 1 (5-4), Figure 5). Therefore, the M203V-rAAV2 variant, which has a higher ratio of [VP1+VP2] / [VP3+VP3 clip], is expected to have a higher gene transfer efficiency (infection efficiency). Therefore, the infection efficiency of each rAAV2 variant was measured in the same manner as in Example 1 (5-4).
[0143] The infection efficiency of each rAAV2 was calculated relative to the infection efficiency of WT-rAAV2 particles corresponding to the Bulk band at an MOI of 1000, and a bar graph was prepared ( Fig. 11B ). Fig. 11B shows that the WT-rAAV2 particles corresponding to the F1.1 band ("F1.1" in Fig. 11B ), M203V-rAAV2 variant particles ("M203V" in Fig. 11B ), and M211V-rAAV2 variant particles ("M211V" in Fig. 11B ) had higher relative infection efficiencies than the WT-rAAV2 particles corresponding to the Bulk band ("Bulk" in Fig. 11B ). As expected, the M203V-rAAV2 variant ("M203V"), which had the highest ratio of [VP1 + VP2] / [VP3 + VP3 clip], had a higher gene transfer efficiency (infection efficiency) than the WT-rAAV2 particles ("F1.1") corresponding to the F1.1 band.
[0144] The relationship between the ratio of [VP1 + VP2] / [VP3 + VP3 clip] and infection efficiency was examined (Fig. 12). Fig. 12 shows a positive correlation between the ratio of [VP1 + VP2] / [VP3 + VP3 clip] and infection efficiency, with the infection efficiency increasing as the ratio of [VP1 + VP2] / [VP3 + VP3 clip] increases.
Claims
1. An adeno-associated virus (AAV) vector particle comprising a capsid, wherein the capsid comprises capsid proteins VP1, VP2, and VP3, and the VP3 is: (A) a polypeptide consisting of an amino acid sequence set forth in any one of SEQ ID NOs: 1 to 6 and 25 to 29; or (B) a polypeptide consisting of an amino acid sequence which contains deletions, substitutions, or additions, or a combination thereof, in the amino acid sequence of the polypeptide of (A) and has at least 80% sequence identity with the amino acid sequence corresponding to amino acids 18 to 533 of the amino acid sequence set forth in SEQ ID NO: 1, and which is capable of forming the capsid, and wherein the ratio of the number of the VP1 and the VP2 to the number of the VP3 in the capsid ([VP1+VP2] / [VP3]) is 0.3 or more.
2. An adeno-associated virus (AAV) vector particle comprising a capsid, the capsid comprising capsid proteins VP1, VP2 and VP3, the VP3 being: (A) a polypeptide consisting of an amino acid sequence set forth in any one of SEQ ID NOs:7 to 18; or (B) a polypeptide consisting of an amino acid sequence which contains deletions, substitutions or additions, or a combination thereof, in the amino acid sequence of the polypeptide of (A) and has at least 80% sequence identity with the amino acid sequence corresponding to amino acids 18 to 533 of the amino acid sequence set forth in SEQ ID NO:1, and which is capable of forming the capsid.
3. The AAV vector particle according to claim 1, wherein the polypeptide (B) is: when an amino acid (referred to as "1stAA" or "9thAA") is present at a position corresponding to the 1st or 9th amino acid in the amino acid sequence set forth in SEQ ID NO:1, the 1stAA or 9thAA is an amino acid selected from the group consisting of methionine, glycine, isoleucine, proline, and serine; when an amino acid sequence corresponding to the amino acid sequence from the 2nd to 8th amino acids (referred to as "2nd-8thAA") in the amino acid sequence set forth in SEQ ID NO:1 is present, the amino acid sequence corresponding to the 2nd-8thAA comprises an amino acid sequence that includes a deletion, substitution, or addition or a combination thereof in the 2nd-8thAA and has at least 70% sequence identity with the 2nd-8thAA; and / or An AAV vector particle, wherein when an amino acid sequence corresponding to the amino acid sequence from 10 to 17 of the amino acid sequence set forth in SEQ ID NO:1 (referred to as "10th-17thAA") is present, the amino acid sequence corresponding to the 10th-17thAA comprises a deletion, substitution or addition, or a combination thereof, in the 10th-17thAA, and has at least 70% sequence identity with the 10th-17thAA.
4. The AAV vector particle according to claim 2, wherein the polypeptide (B) is: when an amino acid (referred to as "1stAA" or "9thAA") is present at a position corresponding to position 1 or 9 of the amino acid sequence set forth in SEQ ID NO:1, the 1stAA or 9thAA is an amino acid selected from the group consisting of valine, glycine, isoleucine, proline, and serine; when an amino acid sequence corresponding to positions 2 to 8 of the amino acid sequence set forth in SEQ ID NO:1 (referred to as "2nd-8thAA") is present, the amino acid sequence corresponding to the 2nd-8thAA comprises an amino acid sequence that contains a deletion, substitution, or addition or a combination thereof in the 2nd-8thAA and has at least 70% sequence identity with the 2nd-8thAA; and / or An AAV vector particle, wherein when an amino acid sequence corresponding to the amino acid sequence from 10 to 17 of the amino acid sequence set forth in SEQ ID NO:1 (referred to as "10th-17thAA") is present, the amino acid sequence corresponding to the 10th-17thAA comprises a deletion, substitution or addition, or a combination thereof, in the 10th-17thAA, and has at least 70% sequence identity with the 10th-17thAA.
5. The AAV vector particle according to claim 2, wherein the ratio of the sum of the number of VP1 and the number of VP2 to the number of VP3 in the capsid ([VP1+VP2] / [VP3]) is 0.3 or more.
6. The AAV vector particle of any one of claims 1 to 5, wherein the AAV vector particle comprises a nucleic acid molecule comprising a predetermined nucleotide sequence.
7. A nucleic acid molecule comprising a polynucleotide sequence encoding VP1, VP2 and VP3, wherein VP3 is: (A) a polypeptide consisting of an amino acid sequence set forth in any one of SEQ ID NOs:7 to 18; or (B) a polypeptide consisting of an amino acid sequence which contains deletions, substitutions or additions, or a combination thereof, in the amino acid sequence of the polypeptide of (A) and has at least 80% sequence identity with the amino acid sequence corresponding to amino acids 18 to 533 of the amino acid sequence set forth in SEQ ID NO:1, and which is capable of forming the capsid.
8. A kit for preparing an AAV vector particle, comprising a first nucleic acid molecule and a second nucleic acid molecule, wherein the first nucleic acid molecule comprises a capsid protein coding region and a Rep region, the second nucleic acid molecule comprises a first adeno-associated virus (AAV) inverted terminal repeat (ITR) sequence; a predetermined nucleotide sequence; and a second AAV-ITR sequence, in this order, the capsid protein coding region comprises a polynucleotide sequence encoding VP1, VP2, and VP3, and the VP3 is: (A) a polypeptide consisting of an amino acid sequence set forth in any one of SEQ ID NOs:7 to 18; or (B) a polypeptide which comprises a deletion, substitution, or addition, or a combination thereof, in the amino acid sequence of the polypeptide of (A), and which consists of an amino acid sequence having at least 80% sequence identity with the amino acid sequence corresponding to amino acids 18 to 533 of the amino acid sequence set forth in SEQ ID NO:1, and which is capable of forming the capsid.
9. An AAV vector particle composition comprising the AAV vector particle according to any one of claims 1 to 5 in a proportion of 50% or more relative to the total moles of the capsid.
10. An AAV vector particle composition comprising the AAV vector particle of claim 6 in a proportion of 50% or more relative to the total moles of said capsid.
11. A pharmaceutical composition comprising an AAV vector particle according to any one of claims 1 to 5.
12. A pharmaceutical composition comprising the AAV vector particle of claim 6.
13. A pharmaceutical composition comprising the AAV vector particle composition of claim 9.
14. An in vitro method for causing transcription and / or expression of a predetermined nucleotide sequence in a mammalian cell, the method comprising contacting a mammalian cell with an AAV vector particle according to claim 6, and placing the cell under conditions permitting the transcription and / or expression of the predetermined nucleotide sequence.
15. An in vitro method for causing transcription and / or expression of a predetermined nucleotide sequence in a mammalian cell, the method comprising: contacting a mammalian cell with an AAV vector particle composition described in claim 9; and placing the cell under conditions that allow transcription and / or expression of the predetermined nucleotide sequence.
Citation Information
Patent Citations
Engineered nucleic acid constructs encoding AAV-produced proteins
JP2022512621A
Novel compositions and methods for recombinant AAV production
JP2023504550A
Cited By
Engineered adeno-associated virus capsid proteins and vectors and uses thereof
CN120842333A
